Our platform
A proprietary manufacturing process for peptide drugs.
Designed to increase manufacturing output for insulin and other peptide drugs, creating a path toward process-ready licensing.
How we create value
Process IP, manufacturing know-how and development work.
rBIO’s objective is to complete scale-up, validate the process at commercial scale, and license the process to qualified partners.
- Insulin-first
- Output-focused
- Built for scale-up
- Intended for licensing
- Expandable to additional peptide drugs over time
Roadmap
The path to process-ready licensing.
rBIO has completed early development work and is preparing for the next stage of process scale-up.
Completed
20L pilot
Early process-development work.
Completed
Exploratory animal study
Safety and efficacy work.
Next milestone
1,000L scale-up
Planned larger-scale validation.
Target
Production ready
Process-ready to license.
Platform highlights
Built for licensing and scale.
Process
Proprietary process IP
Manufacturing process know-how and proprietary IP designed to improve peptide-drug production output.
Output
Designed to double production rate
The process is designed to double the rate of insulin production compared with current industry production.
Scale
Clear development path
20L pilot work is complete and rBIO is preparing for the planned 1,000L scale-up.
Licensing
Partner-enabled model
For qualified drug manufacturers, regional partners, CDMOs, distributors and strategic pharma organizations.
Commercial model
Partner-enabled regional and global adoption.
rBIO’s strategy is to complete the process-development work needed to become license-ready, then support partners in regional and global markets.
This model is intended to reduce execution risk compared with building a fully owned manufacturing footprint from the start.
Partner with rBIO